DC Healthcare Holdings Berhad (“DC Healthcare” or the “Group“), a medical aesthetic services provider specialising in the provision of non-invasive and minimally invasive procedures, today announced its financial results for the first quarter ended 31 March 2025 (“Q1 FY2025”). The Group posted a revenue of RM17.90 million, marking an 89% increase compared to RM9.45 million in the corresponding quarter of the previous year (“Q1 FY2024”).
The strong topline performance was primarily driven by higher redemption rates for aesthetic services and improved cash sales collection, supported by strong consumer interest in aesthetic treatments and expanding service capacity. The aesthetic segment contributed RM14.86 million, or 83% of total revenue, representing a 104% increase from RM7.27 million in Q1 FY2024.
Gross profit also saw a significant improvement, rising to RM9.12 million from RM1.22 million in the same period last year, underscoring operational efficiency and better service realisation. Correspondingly, the Group narrowed its loss before tax (“LBT”) to RM0.84 million, a notable improvement from the RM7.91 million loss recorded in 1Q FY2024.
On a quarter-on-quarter basis, the Group’s revenue improved by 8%, from RM16.61 million in Q4 FY2024 to RM17.90 million in Q1 FY2025, while gross profit rose from RM8.21 million to RM9.12 million, with LBT narrowed from RM3.24 million to RM0.84 million in the current quarter. The improved performance is attributed to the continued increase in treatment volumes, sustained demand, and effective sales conversion efforts.
Dr. Chong Tze Sheng, Managing Director of DC Healthcare commented, “We are encouraged by the strong start to FY2025, with revenue and gross profit showing meaningful improvement. This growth is a reflection of our team’s dedication to enhancing treatment offerings, improving operational execution, and expanding market access. We will continue to prioritise cost discipline and strategic brand positioning to navigate evolving market conditions.”
Looking forward, DC Healthcare remains focused on delivering sustainable growth through several strategic pillars. The Group is strengthening its brand ecosystem by integrating Dr. Chong Clinic, Dr. Chong Slimming, and NewB Premium Skincare, while broadening its skincare product portfolio to capture a larger share of the aesthetic and wellness market.
The Group is also enhancing patient engagement by introducing artificial intelligence-assisted skin analysis and personalised treatment plans, aimed atoptimising treatment outcomes, improving service quality, and driving customer retention.Operational efficiency remains a core priority, with the Group-wide efficiency program and upcoming implementation of an enterprise resource planning (“ERP”) system set to optimise inventory control, resource allocation, and data-driven decision-making.
With these initiatives in place, DC Healthcare is well-positioned to capitalise on Malaysia’s growing aesthetic and wellness market and reinforce its leadership in the industry.
